<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Brain Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Sci</journal-id>
<journal-id journal-id-type="publisher-id">brainsci</journal-id>
<journal-title-group>
<journal-title>Brain Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">2076-3425</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31540439</article-id>
<article-id pub-id-type="pmc">6770198</article-id>
<article-id pub-id-type="doi">10.3390/brainsci9090238</article-id>
<article-id pub-id-type="publisher-id">brainsci-09-00238</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Targeting the Mitochondrial Pyruvate Carrier for Neuroprotection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1925-636X</contrib-id>
<name>
<surname>Tang</surname>
<given-names>Bor Luen</given-names>
</name>
<xref ref-type="aff" rid="af1-brainsci-09-00238">1</xref>
<xref ref-type="aff" rid="af2-brainsci-09-00238">2</xref>
</contrib>
</contrib-group>
<aff id="af1-brainsci-09-00238"><label>1</label>Department of Biochemistry, Yong Loo Lin School of Medicine, National University Health System, Singapore 117596, Singapore; <email>bchtbl@nus.edu.sg</email></aff>
<aff id="af2-brainsci-09-00238"><label>2</label>NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore 119077, Singapore</aff>
<pub-date pub-type="epub">
<day>18</day>
<month>9</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>9</month>
<year>2019</year>
</pub-date>
<volume>9</volume>
<issue>9</issue>
<elocation-id>238</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>8</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>9</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the author.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>The mitochondrial pyruvate carriers mediate pyruvate import into the mitochondria, which is key to the sustenance of the tricarboxylic cycle and oxidative phosphorylation. However, inhibition of mitochondria pyruvate carrier-mediated pyruvate transport was recently shown to be beneficial in experimental models of neurotoxicity pertaining to the context of Parkinson’s disease, and is also protective against excitotoxic neuronal death. These findings attested to the metabolic adaptability of neurons resulting from MPC inhibition, a phenomenon that has also been shown in other tissue types. In this short review, I discuss the mechanism and potential feasibility of mitochondrial pyruvate carrier inhibition as a neuroprotective strategy in neuronal injury and neurodegenerative diseases.</p>
</abstract>
<kwd-group>
<kwd>excitotoxicity</kwd>
<kwd>mitochondrial pyruvate carrier (MPC)</kwd>
<kwd>neuroprotection</kwd>
<kwd>neurotoxicity</kwd>
<kwd>Warburg effect</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-brainsci-09-00238" sec-type="intro">
<title>1. Introduction</title>
<p>Regulatory nodes of energy metabolism have emerged as potential therapeutic targets in multiple human diseases such as cancer, aging and neurodegeneration [<xref ref-type="bibr" rid="B1-brainsci-09-00238">1</xref>,<xref ref-type="bibr" rid="B2-brainsci-09-00238">2</xref>,<xref ref-type="bibr" rid="B3-brainsci-09-00238">3</xref>,<xref ref-type="bibr" rid="B4-brainsci-09-00238">4</xref>,<xref ref-type="bibr" rid="B5-brainsci-09-00238">5</xref>,<xref ref-type="bibr" rid="B6-brainsci-09-00238">6</xref>,<xref ref-type="bibr" rid="B7-brainsci-09-00238">7</xref>]. The 3-Carbon (C) monocarboxylate pyruvate is a key intermediate in energy metabolism [<xref ref-type="bibr" rid="B8-brainsci-09-00238">8</xref>]. During aerobic respiration, pyruvate generated by cytosolic glycolysis is shuttled into the mitochondria matrix, decarboxylated into the 2-C acetyl-CoA, and fed into the tricarboxylic acid (TCA) cycle. Pyruvate could alternatively be carboxylated by pyruvate carboxylase in an anaplerotic mode to form oxaloacetate (OAA). The above mitochondrial metabolic modes of pyruvate are dependent on pyruvate import from the cytosol by mitochondrial pyruvate carrier (MPC) [<xref ref-type="bibr" rid="B9-brainsci-09-00238">9</xref>,<xref ref-type="bibr" rid="B10-brainsci-09-00238">10</xref>]. Postmitotic brain neurons are energetically intensive cell types [<xref ref-type="bibr" rid="B11-brainsci-09-00238">11</xref>], and maintenance of the neuronal membrane polarization resting potential under normal functional conditions is very much dependent on efficient ATP generation via oxidative phosphorylation. In other words, a constant supply of pyruvate generated from glucose [<xref ref-type="bibr" rid="B12-brainsci-09-00238">12</xref>] to the mitochondria is pivotal for neuronal function and survival. In times of heightened activities and injury, lactate provided by the astrocyte-neuron lactate shuttle plays an important role in ensuring pyruvate availability [<xref ref-type="bibr" rid="B13-brainsci-09-00238">13</xref>]. In fact, a good number of studies have shown that exogenous pyruvate is neuroprotective in hypoglycemic episodes [<xref ref-type="bibr" rid="B14-brainsci-09-00238">14</xref>], ischemic, epileptic or neurotoxic injuries [<xref ref-type="bibr" rid="B15-brainsci-09-00238">15</xref>,<xref ref-type="bibr" rid="B16-brainsci-09-00238">16</xref>,<xref ref-type="bibr" rid="B17-brainsci-09-00238">17</xref>,<xref ref-type="bibr" rid="B18-brainsci-09-00238">18</xref>,<xref ref-type="bibr" rid="B19-brainsci-09-00238">19</xref>], as well as neurodegenerative conditions [<xref ref-type="bibr" rid="B20-brainsci-09-00238">20</xref>,<xref ref-type="bibr" rid="B21-brainsci-09-00238">21</xref>]. From another perspective, dysfunctions and abnormalities in mitochondrial energetics underlie many neurological disorders and neurodegenerative diseases [<xref ref-type="bibr" rid="B22-brainsci-09-00238">22</xref>,<xref ref-type="bibr" rid="B23-brainsci-09-00238">23</xref>,<xref ref-type="bibr" rid="B24-brainsci-09-00238">24</xref>], and contributed to neuronal demise during injury [<xref ref-type="bibr" rid="B25-brainsci-09-00238">25</xref>]. In this regard, improving mitochondrial energetics dysfunction would be beneficial to disease outcome.</p>
<p>In view of the above, it may, therefore, be somewhat non-intuitive but interesting that the inhibition of pyruvate transport by MPC was recently shown to be beneficial in experimental models of neurotoxicity, particularly in the context of Parkinson’s disease (PD) models [<xref ref-type="bibr" rid="B26-brainsci-09-00238">26</xref>], and is also protective against excitotoxic neuronal death [<xref ref-type="bibr" rid="B27-brainsci-09-00238">27</xref>]. These findings, and the possibility of MPC inhibition as a neuroprotective strategy in neuronal injury and neurodegenerative diseases, shall be the focus of the discussion below.</p>
</sec>
<sec id="sec2-brainsci-09-00238">
<title>2. The Mitochondria Pyruvate Carrier</title>
<p>The mechanism underlying mitochondrial cytosolic pyruvate transport into the mitochondrial matrix has been of great interest. However, this is better understood only recently with the identification of the mitochondria pyruvate carriers (MPC) [<xref ref-type="bibr" rid="B10-brainsci-09-00238">10</xref>,<xref ref-type="bibr" rid="B28-brainsci-09-00238">28</xref>], which are non-canonical transporters unrelated to the classically recognized carboxylate transporters encoded by the <italic>SLC25A</italic> gene family [<xref ref-type="bibr" rid="B9-brainsci-09-00238">9</xref>,<xref ref-type="bibr" rid="B29-brainsci-09-00238">29</xref>]. Cytosolic pyruvate cannot access the mitochondrial matrix by diffusion across the inner mitochondrial membrane (IMM). Early work by Halestrap and colleagues have shown that pyruvate uptake by isolated mitochondria exhibited saturation kinetics and identified specific inhibitors for the process, such as UK-5099 (2-Cyano-3-(1-phenyl-1H-indol-3-yl)-2-propenoic acid) [<xref ref-type="bibr" rid="B30-brainsci-09-00238">30</xref>], all of which attested to the notion that mitochondrial pyruvate transport occurs via specific carriers [<xref ref-type="bibr" rid="B31-brainsci-09-00238">31</xref>]. A putative MPC candidate subsequently identified in yeast [<xref ref-type="bibr" rid="B32-brainsci-09-00238">32</xref>] was, however, later shown to be a NAD<sup>+</sup> transporter [<xref ref-type="bibr" rid="B33-brainsci-09-00238">33</xref>]. </p>
<p>The true MPC paralogues were eventually identified in yeast, <italic>Drosophila</italic> and mouse in 2012 by the laboratories of Rutter [<xref ref-type="bibr" rid="B34-brainsci-09-00238">34</xref>] and Martinou [<xref ref-type="bibr" rid="B35-brainsci-09-00238">35</xref>]. Both groups were studying two conserved paralogues with unknown function, Brain protein 44 (BRP44) and BRP44-like (BRP44L) (subsequently human MPC2 and MPC1, respectively). The compelling cellular, biochemical and functional evidences accompanying these works included the severe impairment of mitochondria pyruvate import in yeast Mpc1 mutants, and that expression of mammalian MPC1 and MPC2 in the bacteria <italic>Lactococcus lactis</italic> conferring pyruvate uptake activity characteristic of eukaryotic UK-5099-sensitive mitochondrial pyruvate import [<xref ref-type="bibr" rid="B35-brainsci-09-00238">35</xref>]. The discovery of MPCs has been extensively reviewed, and interested readers are hereby referred to these excellent accounts [<xref ref-type="bibr" rid="B9-brainsci-09-00238">9</xref>,<xref ref-type="bibr" rid="B28-brainsci-09-00238">28</xref>,<xref ref-type="bibr" rid="B36-brainsci-09-00238">36</xref>].</p>
<p><italic>S. cerevisiae</italic> has three MPC paralogues, while mouse has two. Placental mammals have an additional paralogue MPC1-like (MPC1L), which is expressed almost exclusively in the testis, particularly in postmeiotic spermatids and sperm cells [<xref ref-type="bibr" rid="B37-brainsci-09-00238">37</xref>]. MPC has also been described in plants, and the <italic>Arabidopsis</italic> MPC orthologue NRGA1 is a negative regulator of guard cell abscisic acid signaling by affecting cellular pyruvate content [<xref ref-type="bibr" rid="B38-brainsci-09-00238">38</xref>,<xref ref-type="bibr" rid="B39-brainsci-09-00238">39</xref>]. Genetic deletion of all three yeast paralogues is tolerated in rich medium, but even the <italic>mpc1</italic>Δ and <italic>mpc2</italic>Δ mutants exhibit measurable growth impairment in non-fermentable carbon sources or with amino acid depletion [<xref ref-type="bibr" rid="B35-brainsci-09-00238">35</xref>]. Moreover, cellular changes and adaptations in <italic>mpc1</italic>Δ mutants tend to increase oxidative damage of the mitochondria and restrict cell survival during yeast chronological aging [<xref ref-type="bibr" rid="B40-brainsci-09-00238">40</xref>]. Genetic ablation of either MPC1 [<xref ref-type="bibr" rid="B41-brainsci-09-00238">41</xref>] or MPC2 [<xref ref-type="bibr" rid="B42-brainsci-09-00238">42</xref>] in mouse resulted in embryonic lethality. Point mutations in human MPC1 [<xref ref-type="bibr" rid="B34-brainsci-09-00238">34</xref>,<xref ref-type="bibr" rid="B43-brainsci-09-00238">43</xref>] are known to result in impairment of pyruvate oxidation with affected individuals presented with developmental abnormality, neurological problems and metabolic deficits. </p>
<p>Cross-species complementation of <italic>S. cerevisiae mpc1</italic>Δ mutant indicate that Mpc1 function is evolutionarily conserved but has non-overlapping roles with Mpc2. MPC1 and MPC2 could homo- and hetero-oligomerize and form large ~150 kDa complexes. Human MPC2 has been shown to mediate efficient pyruvate transport into proteoliposomes alone, and its expression in Mpc-deficient yeast stimulated growth and increased oxygen consumption [<xref ref-type="bibr" rid="B44-brainsci-09-00238">44</xref>]. However, the functional unit for MPC’s pyruvate carrier function is most likely a MPC1-MPC2 heterodimer [<xref ref-type="bibr" rid="B34-brainsci-09-00238">34</xref>,<xref ref-type="bibr" rid="B45-brainsci-09-00238">45</xref>,<xref ref-type="bibr" rid="B46-brainsci-09-00238">46</xref>]. For yeast, while Mpc1 expression does not change with different carbon sources, the other two paralogues are specifically expressed under fermentative (Mpc2) or respiratory (Mpc3) conditions [<xref ref-type="bibr" rid="B47-brainsci-09-00238">47</xref>,<xref ref-type="bibr" rid="B48-brainsci-09-00238">48</xref>]. The Mpc3-containing carrier complex has higher pyruvate transport activity compared to that containing Mpc2, and alternative Mpc2/3 expression likely serves as an adaptive response to nutrient availability [<xref ref-type="bibr" rid="B48-brainsci-09-00238">48</xref>].</p>
</sec>
<sec id="sec3-brainsci-09-00238">
<title>3. Metabolic Insights Arising from the Manipulation of MPC Levels and Activity</title>
<p>The identification of the MPC paralogues has led quickly to some experimental insights on its systemic role in mammalian energy metabolism. One prominent role for MPC is in glucose-stimulated insulin secretion. Pharmacological inhibition or expression silencing of MPC in pancreatic β-cells [<xref ref-type="bibr" rid="B49-brainsci-09-00238">49</xref>] blocked the glucose-stimulated increase in insulin secretion, while UK-5099 administration caused impaired glucose tolerance [<xref ref-type="bibr" rid="B49-brainsci-09-00238">49</xref>]. Glucose intolerance is likewise observed for a MPC2 hypomorphic mouse line harboring an N-terminally truncated protein, a phenotype that could be attributed to an impairment in glucose-stimulated pancreatic insulin released [<xref ref-type="bibr" rid="B42-brainsci-09-00238">42</xref>]. In this connection, a particularly important finding is that the anti-diabetic drug family of thiazolidinediones (TZDs), known previously as peroxisome proliferator-activated receptor gamma (PPARγ) agonists [<xref ref-type="bibr" rid="B50-brainsci-09-00238">50</xref>,<xref ref-type="bibr" rid="B51-brainsci-09-00238">51</xref>], turned out to be MPC inhibitors at clinically relevant concentrations [<xref ref-type="bibr" rid="B45-brainsci-09-00238">45</xref>,<xref ref-type="bibr" rid="B52-brainsci-09-00238">52</xref>]. MPC1 and MPC2 were identified as mitochondrial proteins that could be chemically cross-linked to TZD in a manner that could be blocked by UK-5099, thus the term “mitochondrial target of TZDs” (mTOT) [<xref ref-type="bibr" rid="B52-brainsci-09-00238">52</xref>,<xref ref-type="bibr" rid="B53-brainsci-09-00238">53</xref>]. In fact, a TZD analog MSDC-0602, with very low affinity for binding and activation of PPAR<italic>γ</italic>, could nonetheless exert significant pharmacological effects on insulin sensitivity, and improve metabolic derangements in mice with liver-specific PPARγ knockout [<xref ref-type="bibr" rid="B54-brainsci-09-00238">54</xref>]. MPC inhibition by TZD also underlies its stimulation of glucose uptake in myotubes and myocytes, and UK-5099 mimicked TZD’s activation of AMP-activated protein kinase (AMPK) [<xref ref-type="bibr" rid="B45-brainsci-09-00238">45</xref>]. These findings attested to the importance of mitochondrial pyruvate uptake as a key regulatory node in acute glucose sensing and uptake. </p>
<p>On the other hand, defective mitochondrial pyruvate uptake is also associated with aberrant metabolism in diseased cells and tissues. For example, cancer cells have altered energy metabolism, often termed the Warburg effect [<xref ref-type="bibr" rid="B55-brainsci-09-00238">55</xref>,<xref ref-type="bibr" rid="B56-brainsci-09-00238">56</xref>], which is associated with a tendency for cancerous cells to generate lactate from pyruvate and have reduced aerobic oxidation even under normoxic and aerobic conditions. The Warburg effect has been associated with an elevation in pyruvate kinase isoform M2 [<xref ref-type="bibr" rid="B57-brainsci-09-00238">57</xref>] and a decrease in pyruvate production, an upregulation of lactate dehydrogenase (LDH) [<xref ref-type="bibr" rid="B58-brainsci-09-00238">58</xref>], or an inhibition of pyruvate dehydrogenase (PDH) by the induction of pyruvate dehydrogenase kinase 1 (PDK1) under hypoxic conditions common to solid tumors [<xref ref-type="bibr" rid="B59-brainsci-09-00238">59</xref>]. However, the Warburg effect could also be due to a loss of MPC1 and consequential impairment of mitochondrial pyruvate transport in multiple cancer types [<xref ref-type="bibr" rid="B60-brainsci-09-00238">60</xref>,<xref ref-type="bibr" rid="B61-brainsci-09-00238">61</xref>,<xref ref-type="bibr" rid="B62-brainsci-09-00238">62</xref>,<xref ref-type="bibr" rid="B63-brainsci-09-00238">63</xref>,<xref ref-type="bibr" rid="B64-brainsci-09-00238">64</xref>,<xref ref-type="bibr" rid="B65-brainsci-09-00238">65</xref>,<xref ref-type="bibr" rid="B66-brainsci-09-00238">66</xref>,<xref ref-type="bibr" rid="B67-brainsci-09-00238">67</xref>]. MPC1 expression and activity appears to limit malignancy [<xref ref-type="bibr" rid="B60-brainsci-09-00238">60</xref>,<xref ref-type="bibr" rid="B68-brainsci-09-00238">68</xref>], suppress the expressions of stemness markers [<xref ref-type="bibr" rid="B60-brainsci-09-00238">60</xref>,<xref ref-type="bibr" rid="B64-brainsci-09-00238">64</xref>,<xref ref-type="bibr" rid="B69-brainsci-09-00238">69</xref>,<xref ref-type="bibr" rid="B70-brainsci-09-00238">70</xref>], and influences epithelial-mesenchymal transition [<xref ref-type="bibr" rid="B66-brainsci-09-00238">66</xref>,<xref ref-type="bibr" rid="B71-brainsci-09-00238">71</xref>]. On the other hand, MPC inhibition has been shown to have an antitumor effect, in blocking lactate uptake and sensitizing tumor xenografts to radiotherapy [<xref ref-type="bibr" rid="B72-brainsci-09-00238">72</xref>].</p>
<p>Given the apparently critical importance of mitochondrial pyruvate transport, would there be sufficient room for maneuver in engaging MPCs as drug targets? Would MPC inhibition detrimentally diminish ATP production or critically paralyze the TCA cycle’s energetic and anaplerotic [<xref ref-type="bibr" rid="B73-brainsci-09-00238">73</xref>] roles? Studies with MPC silencing or inhibition with cells in culture have in fact indicated a surprising degree of cellular metabolic flexibility and adaptation associated with acute loss of MPC activity. While loss of MPC resulted in a significant reduction in both glucose and pyruvate oxidation, cell growth, oxygen consumption, and the TCA cycle functionality in general were apparently not drastically affected. Yang and colleagues showed using SFxL glioma cells [<xref ref-type="bibr" rid="B74-brainsci-09-00238">74</xref>] that pyruvate import suppresses mitochondrial glutamate dehydrogenase (GDH) and glutamine-dependent acetyl-CoA formation [<xref ref-type="bibr" rid="B75-brainsci-09-00238">75</xref>]. MPC inhibition by UK-5099 activated GDH, thus rerouting glutamine metabolism to generate both oxaloacetate and acetyl-CoA to maintain TCA cycle function, as well as for lipid synthesis [<xref ref-type="bibr" rid="B75-brainsci-09-00238">75</xref>]. Vacanti and colleagues also showed that for C2C12 myoblasts with MPC knockdown, TCA flux was maintained by enhanced glutaminolysis through the malic enzyme and pyruvate dehydrogenase (PDH), as well as through fatty acid and branched-chain amino acid oxidation [<xref ref-type="bibr" rid="B76-brainsci-09-00238">76</xref>]. </p>
<p>More recent studies have also demonstrated systemic effects that are non-detrimental with tissue type specific <italic>MPC</italic> knockouts. Gray and colleagues showed that liver-specific knockout of MPC1 markedly decreased pyruvate-driven gluconeogenesis and induced adaptive utilization of glutamine. Constitutive hepatic MPC1 deletion attenuated the development of hyperglycemia induced by a high-fat diet. Even acute MPC1 deletion in hepatocytes (in <italic>MPC</italic> floxed (<italic>MPC1<sup>fl/fl</sup>)</italic> littermates treated with AAV-Cre driven by a hepatocyte-specific promoter) after diet-induced obesity decreased hyperglycemia and improved glucose tolerance [<xref ref-type="bibr" rid="B77-brainsci-09-00238">77</xref>]. McCommis and colleagues found that mice with a liver-specific knockout of MPC2 had impaired conversion of labeled pyruvate to TCA cycle intermediates and glucose [<xref ref-type="bibr" rid="B78-brainsci-09-00238">78</xref>], which impairs gluconeogenesis and apparently protects the animals from hyperglycemia. Blood glucose levels were in fact maintained by pyruvate-alanine cycling, and glucose production by MPC2-deficient hepatocytes could thus be effectively reduced by inhibition of pyruvate-alanine transamination [<xref ref-type="bibr" rid="B78-brainsci-09-00238">78</xref>]. On the other hand, Sharma and colleagues showed that muscle-specific MPC deletion in mouse diverted pyruvate mitochondrial import into circulating lactate and increased muscle fatty acid oxidation and decreased adiposity [<xref ref-type="bibr" rid="B79-brainsci-09-00238">79</xref>]. In fact, muscle glucose uptake and whole-body insulin sensitivity were also increased. Importantly, these studies show that targeted inhibition of MPC may be beneficial to pathological conditions of obesity and hyperglycemia associated with type 2 diabetes mellitus (T2DM). They would also suggest that the antidiabetic effects of TZDs may act, at least partially, through MPC inhibition.</p>
</sec>
<sec id="sec4-brainsci-09-00238">
<title>4. MPC Inhibition and Neuroprotection</title>
<p>Considering the effect of MPC loss or inhibition on metabolic changes at the cellular and organismal level, it is conceivable that MPC inhibition may confer benefits in certain diseased conditions. However, for postmitotic brain neurons that are critically dependent on glucose or lactate fueled high intensity energy metabolism and ATP production for their survival and functionality, pyruvate is known to be neuroprotective in different neuropathological contexts. Whether acute MPC inhibition could even be tolerated by brain neurons is doubtful. It is therefore somewhat surprising that MPC inhibition has been shown to confer protective benefits in two somewhat different aspects of neuroprotection, namely dopaminergic neuronal death in PD models and excitotoxic neuronal death due to glutamate. We now turn to these cases.</p>
<sec id="sec4dot1-brainsci-09-00238">
<title>4.1. MPC Inhibition and Protection against Neurotoxic Compounds and Factors</title>
<p>Ghosh and colleagues have examined the effect of the MPC-specific TZD, MSDC-0160, in dopaminergic neuron protection using several different PD models [<xref ref-type="bibr" rid="B26-brainsci-09-00238">26</xref>]. The authors found that MSDC-0160 protected tyrosine hydroxylase (TH)-expressing differentiated Lund human mesencephalic (LUHMES) cells, TH-positive mouse primary mesencephalic neurons in culture, as well as GFP-labelled dopaminergic neurons in <italic>C. elegans</italic>, against the neurotoxicity of 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>). MSDC-0160 also rescued dopaminergic neurons in <italic>C. elegans</italic> expressing the human PD-associated A53T mutant of <italic>α</italic>-synuclein from degeneration. In mouse, systemically administered MSDC-0160 could effectively enter brain tissues. In a PD mouse model in which animal brains were lesioned with the MPP<sup>+</sup> precursor 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), MSDC-0160 treatment, either pre- or post-MPTP administration elicited an array of beneficial effects. Locomotor behavioural function, nigral dopaminergic neuron survival, and striatal dopamine levels were improved while neuroinflammation was reduced. In another mouse model in which heterozygocity of Engrailed1 (<italic>En1</italic><sup>+/−</sup>) produces a progressive nigrostriatal degeneration phenotype [<xref ref-type="bibr" rid="B80-brainsci-09-00238">80</xref>], MSDC-0160 administration from either 3 or 8 weeks of age significantly preserved motor function, TH-positive neuron viability, striatal content of dopamine and its metabolite, as well as reduced neuroinflammation. Thus, it appears that MPC inhibition protects against classical neurotoxins like MPTP and its active metabolite MPP<sup>+</sup>, as well as neurotoxicity incurred by mutant α-synuclein.</p>
<p>How exactly does MSDC-0160 exert its neuroprotective effect as an MPC inhibitor? Ghosh and colleagues hypothesized that neuroprotection may involve the mechanistic target of rapamycin (mTOR) pathway, which functions downstream of MPC activity [<xref ref-type="bibr" rid="B81-brainsci-09-00238">81</xref>]. mTOR inhibition has indeed been associated with benefits in aging and neurodegeneration [<xref ref-type="bibr" rid="B82-brainsci-09-00238">82</xref>], particularly through modulation of autophagy [<xref ref-type="bibr" rid="B83-brainsci-09-00238">83</xref>]. In this regard, Ghosh and colleagues have also shown that MSDC-0160′s beneficial effects were dependent on a non-acute, negative modulation of the mTOR pathway as demonstrated by reduced phosphorylation of mTOR and its substrate p70S6 kinase, which likely resulted from the more acute perturbative action on mitochondrial metabolism. Furthermore, MSDC-0160 induced mitochondrial metabolic changes could likely reduce astrogliosis and microgliosis by reducing NF-κB based inflammatory signaling in glial cells in a manner that also involves mTOR inhibition, with the latter having been shown to downregulate brain neuroinflammation in other contexts [<xref ref-type="bibr" rid="B84-brainsci-09-00238">84</xref>,<xref ref-type="bibr" rid="B85-brainsci-09-00238">85</xref>,<xref ref-type="bibr" rid="B86-brainsci-09-00238">86</xref>]. In summary, MPC inhibition could be neuroprotective via a mTOR signaling modulation in both a neuron cell-autonomous manner through metabolic changes and adaptation, as well as a reduction of neuroinflammation mediated by glial cells.</p>
</sec>
<sec id="sec4dot2-brainsci-09-00238">
<title>4.2. MPC Inhibition and Protection against Glutamate Excitotoxicity</title>
<p>In another key report, Divakaruni and colleagues investigated the effect of MPC inhibition in excitotoxic neuronal death [<xref ref-type="bibr" rid="B27-brainsci-09-00238">27</xref>]. The authors found that unlike the respiratory chain inhibitor antimycin A (a cytochrome c reductase inhibitor) which causes death, rat cortical neurons maintained in culture with the MPC inhibitor UK-5099 remain viable for 3 days or more despite having their pyruvate oxidizing capacity reduced by more than half. Interestingly, the neurons appeared to rather readily oxidize other substrates, such as leucine and β-hydroxybutyrate, when supplemented in customized media during UK-5099 treatment. These non-glucose substrates could reverse alterations in glycolytic rate and total ATP production with MPC inhibition, and stable isotope tracings showed that these non-glucose substrates contributed significantly to the acetyl-CoA pool and TCA cycle intermediates. In rich media, incorporation of glucose-derived C into the TCA cycle intermediates was significant reduced byUK-5099 treatment, but basal metabolic rate is maintained and there was no substantial elevation of cellular lactate levels. Interestingly, however, oxidation of leucine and β-hydroxybutyrate were also not substantially increased during MPC inhibition in rich medium, indicating that pyruvate transport inhibited neurons have adapted metabolically by oxidising another substrate. </p>
<p>A profiling of metabolites and TCA cycle intermediates showed, among expected changes in citrate and alanine, UK5099 treatment reduced total glutamate levels by half, whereas there was a twofold increase in aspartate. This suggests an increased in oxidation of glutamate (or glutamine), which could occur via aspartate aminotransferase or oxidative deamination by glutamate dehydrogenase [<xref ref-type="bibr" rid="B87-brainsci-09-00238">87</xref>,<xref ref-type="bibr" rid="B88-brainsci-09-00238">88</xref>], and has been demonstrated in other cell/tissue types with MPC inhibition [<xref ref-type="bibr" rid="B75-brainsci-09-00238">75</xref>,<xref ref-type="bibr" rid="B77-brainsci-09-00238">77</xref>,<xref ref-type="bibr" rid="B89-brainsci-09-00238">89</xref>]. In neurons, this is not known to occur to any significant degree as neuronal cell glutamate is usually associated with the neurotransmitter pool at the synaptic compartments. Isotope tracing with labelled glutamine showed that UK-5099 treatment indeed increased glutamine uptake and C fluxes of glutamine-derived Acetyl-CoA to TCA cycle intermediates. The authors also hypothesized that the preferred oxidation of glutamate, but not other substrates, could reflect a cellular adaptation to compensate for loss in pyruvate-based anaplerosis. This notion is supported by the observation that the labelled third C of the [3-<sup>13</sup>C1] glucose tracer found in TCA cycle intermediates were significantly diminished by UK-5099. The reciprocal regulation of pyruvate and glutamate oxidation could also be discerned to some degree in UK-5099 treated organotypic hippocampal slice cultures with mixed neural cell types. </p>
<p>Perhaps the most intriguing finding of Divakaruni and colleagues is that this glutamate oxidation promoted by MPC inhibition could ultimately be neuroprotective. Glutamate is an excitatory neurotransmitter, and its uncontrolled release during massive glutamatergic neuron depolarization, resulting from acute oxygen-glucose depletion accompanying ischemic or traumatic injury, mediates excitotoxic neuronal death. Use of neuronal glutamate for oxidation may conceivably decrease the glutamate released upon depolarization, and could thus limit excitotoxic neuronal injury. Indeed, neurons treated with UK-5099 released less glutamate extracellularly upon depolarization induced by veratridine (which prevents sodium channel closure), ouabain (which inhibits Na<sup>+</sup>/K<sup>+</sup>-ATPase) and an N-methyl aspartate (NMDA) pulse. Furthermore, cortical neurons treated with UK-5099 were protected from excitotoxic cell death by glutamate added in culture medium in a non-additive manner to the protective effects of the excitotoxicity-mediating NMDA receptor antagonist MK801. Post-synaptic currents in neurons treated with UK-5099 also produced a smaller current density peak in excitatory postsynaptic current elicited by a hypertonic sucrose shock. Together, these findings therefore suggest that enhancing glutamate oxidation by MPC inhibition could indeed attenuate the glutamate pool released upon depolarization. </p>
</sec>
</sec>
<sec id="sec5-brainsci-09-00238">
<title>5. Caveats and Unanswered Questions</title>
<p>The above findings indicating that MPC inhibition is neuroprotective gave rise to many intriguing questions. Although MSDC-0160-mediated neuroprotection could be largely attributed to MPC inhibition, it is yet unclear exactly how the protective benefit arises. Ghosh and colleagues have made observations that are suggestive of inhibition of mTOR signaling. However, whether this accounts for the neuroprotective effect was not confirmed. Furthermore, how mTOR signaling, particularly through the mTORC1 complex [<xref ref-type="bibr" rid="B90-brainsci-09-00238">90</xref>], could be affected by MPC inhibition is yet unclear. One possibility is the elevation of AMP/ATP ratio activated AMP-dependent kinase (AMPK) [<xref ref-type="bibr" rid="B91-brainsci-09-00238">91</xref>] (see <xref ref-type="fig" rid="brainsci-09-00238-f001">Figure 1</xref>). AMPK could suppress mTORC1 signaling through the phosphorylation of Raptor [<xref ref-type="bibr" rid="B92-brainsci-09-00238">92</xref>], thus excluding it from the functional mTORC1 complex, or the phosphorylation of the tumor suppressor Tuberous sclerosis complex 2 (TSC2) [<xref ref-type="bibr" rid="B93-brainsci-09-00238">93</xref>], a key negative regulator of mTORC1 in conjunction with TSC1 [<xref ref-type="bibr" rid="B94-brainsci-09-00238">94</xref>]. Exerting neuroprotection via AMPK activation [<xref ref-type="bibr" rid="B95-brainsci-09-00238">95</xref>,<xref ref-type="bibr" rid="B96-brainsci-09-00238">96</xref>] is also a major mechanism underlying the neuroprotective effect of another first-line diabetic drug, the dimethylbiguanide metformin [<xref ref-type="bibr" rid="B97-brainsci-09-00238">97</xref>,<xref ref-type="bibr" rid="B98-brainsci-09-00238">98</xref>]. Given the complexity of metabolic adaptation that ensues upon MPC inhibition, whether neuroprotection could be largely explained by inhibition of mTORC1 through AMPK activation needs further experimental verification.</p>
<p>Pertaining to the findings of Divakaruni and colleagues, the details of metabolic adaptation resulting from inhibition of mitochondrial pyruvate transport leading to an enhanced glutamate oxidation are also unclear. There are several questions that need to be addressed. Firstly, despite the inhibition of mitochondrial import, could mitochondrial pyruvate levels be nonetheless sustained by other pathways? In the classically known Cahill cycle (or glucose-alanine cycle) [<xref ref-type="bibr" rid="B99-brainsci-09-00238">99</xref>] between muscle and liver, muscles degrade amino acids for energy needs with alanine transaminase (ALT), which converts glutamate and pyruvate into α-ketoglutarate and alanine. ALT is present in both cytosol and the mitochondria and could potentially sustain the level of mitochondrial pyruvate using alanine. However, its expression is limited to tissues like muscle and liver, and whether there are any significant ALT activities in neurons is unclear. Another possible way to sustain mitochondrial pyruvate is the conversion of malate to pyruvate by malate dehydrogenase, with malate generated from glutamine or glutamate’s conversion to <italic>α</italic>-ketoglutarate by glutamate dehydrogenase (GDH), thus feeding into the TCA cycle (<xref ref-type="fig" rid="brainsci-09-00238-f001">Figure 1</xref>). A switch from fueling the TCA cycle with glutamine rather than glucose is indeed a feature of cancer cells [<xref ref-type="bibr" rid="B100-brainsci-09-00238">100</xref>]. </p>
<p>The data of Divakaruni and colleagues appear to suggest that the synaptic glutamate pool of glutamatergic neurons may plausibly equilibrate with that of the mitochondria, thus increasing mitochondrial glutamate. How this might occur is not particularly clear. The mitochondrial glutamate carrier 1 (SLC25A22) [<xref ref-type="bibr" rid="B101-brainsci-09-00238">101</xref>] is mainly astrocytic, and whether it is upregulated in neurons as a result of MPC inhibition to mediate glutamate import into the mitochondrial would be a point that deserves further investigation. In γ-aminobutyric acid (GABA)ergic neurons, glutamine is actively taken up as a precursor for GABA synthesis. Glutamine can be converted to glutamate by glutaminase, and in theory therefore, the same mechanism of alternative substrate oxidation could sustain MPC-inhibited GABAergic neurons as well. How different neuronal types adapt to an inhibition of mitochondrial pyruvate transport would be of significant interest in the immediate future. </p>
</sec>
<sec id="sec6-brainsci-09-00238">
<title>6. Is MPC Inhibition a Viable Strategy for Neuroprotection?</title>
<p>Given the critical role of MPCs in mammalian development and the problems of patients harboring MPC mutations, MPC inhibition might be perceived as being overly detrimental for cellular and organismal energetics and survival to be of benefit. However, as the findings above in liver, muscle and neurons have demonstrated, genetic ablation or pharmacological inhibition of MPC activities could be contextually beneficial in diseased conditions. This is very much down to the previously underappreciated metabolic adaptability exhibited under the condition of mitochondrial pyruvate transport inhibition. As far as neuropathological conditions are concerned, a metabolic shift to the usage of glutamine/glutamate that would reduce glutamate release and excitotoxicity, as well as the possibility of mTOR pathway inhibition that could lead to elevated autophagy and suppression of neuroinflammation, would constitute neuroprotective benefits. The reprogramming of mitochondrial metabolism resulting from MPC inhibition could therefore provide context-dependent benefits under neuronal disease conditions, which could potentially also be extended to diseases in other organs or tissues.</p>
<p>There are also indications that MPC inhibition could be beneficial in other neuropathological conditions. TZDs have been shown to be beneficial for a range of neurodegenerative diseases, including Alzheimer’s disease (AD) [<xref ref-type="bibr" rid="B102-brainsci-09-00238">102</xref>,<xref ref-type="bibr" rid="B103-brainsci-09-00238">103</xref>,<xref ref-type="bibr" rid="B104-brainsci-09-00238">104</xref>,<xref ref-type="bibr" rid="B105-brainsci-09-00238">105</xref>], PD [<xref ref-type="bibr" rid="B106-brainsci-09-00238">106</xref>,<xref ref-type="bibr" rid="B107-brainsci-09-00238">107</xref>,<xref ref-type="bibr" rid="B108-brainsci-09-00238">108</xref>,<xref ref-type="bibr" rid="B109-brainsci-09-00238">109</xref>,<xref ref-type="bibr" rid="B110-brainsci-09-00238">110</xref>], Amyotrophic lateral sclerosis [<xref ref-type="bibr" rid="B111-brainsci-09-00238">111</xref>,<xref ref-type="bibr" rid="B112-brainsci-09-00238">112</xref>], and Huntington’s disease [<xref ref-type="bibr" rid="B113-brainsci-09-00238">113</xref>,<xref ref-type="bibr" rid="B114-brainsci-09-00238">114</xref>,<xref ref-type="bibr" rid="B115-brainsci-09-00238">115</xref>]. AD’s pathological connections with T2DM has in particular led to it being termed as Type 3 diabetes mellitus [<xref ref-type="bibr" rid="B116-brainsci-09-00238">116</xref>], and emerging data on the underlying mechanisms in cognitive decline or dementia due to brain insulin resistance [<xref ref-type="bibr" rid="B117-brainsci-09-00238">117</xref>,<xref ref-type="bibr" rid="B118-brainsci-09-00238">118</xref>] would point towards TZDs being potentially disease-modifying or symptom-alleviating in AD [<xref ref-type="bibr" rid="B119-brainsci-09-00238">119</xref>]. Recent meta-analyses have also indicated that pioglitazone use reduced stroke events in T2DM patients [<xref ref-type="bibr" rid="B120-brainsci-09-00238">120</xref>], and is also associated with a reduced incidence of secondary stroke [<xref ref-type="bibr" rid="B121-brainsci-09-00238">121</xref>,<xref ref-type="bibr" rid="B122-brainsci-09-00238">122</xref>]. Furthermore, pioglitazone administration in rat chronic TBI model improved working memory [<xref ref-type="bibr" rid="B123-brainsci-09-00238">123</xref>]. Although the neuroprotective and beneficial effects of the TZDs in neuropathology are usually attributed to PPARγ activation, in retrospection their inhibition of MPCs may have been at least partially responsible.</p>
<p>What then, are the clinical prospects of MPC inhibition in neuroprotection? TZDs which are standard diabetic drugs with ample clinical testing already done, have been and should be further investigated in trials [<xref ref-type="bibr" rid="B124-brainsci-09-00238">124</xref>]. The aerobic glycolysis-inhibiting cancer drug lonidamine has also been shown to be a potent MPC inhibitor [<xref ref-type="bibr" rid="B125-brainsci-09-00238">125</xref>], has low toxicity [<xref ref-type="bibr" rid="B126-brainsci-09-00238">126</xref>,<xref ref-type="bibr" rid="B127-brainsci-09-00238">127</xref>] and has been used in multiple clinical trials in cancer [<xref ref-type="bibr" rid="B126-brainsci-09-00238">126</xref>,<xref ref-type="bibr" rid="B128-brainsci-09-00238">128</xref>]. Given that lonidamine inhibits MPC with a Ki of 2.5 µM and an IC50 of ~20 µM [<xref ref-type="bibr" rid="B125-brainsci-09-00238">125</xref>] and that plasma concentrations exceeding its IC50 could be easily achieved in patients with little toxicity [<xref ref-type="bibr" rid="B126-brainsci-09-00238">126</xref>], its used for neurological conditions appears feasible. Long-term use of stronger inhibitors such as UK-5099 (IC50, 50 nM) may not be feasible but its acute application may be tolerated. This would need to be determined in preliminary trials.</p>
</sec>
<sec id="sec7-brainsci-09-00238" sec-type="conclusions">
<title>7. Conclusions</title>
<p>As an epilogue, therefore, findings in neuroprotection resulting from MPC inhibition are intriguing. Although there is much more to be learned before the underlying mechanisms are fully explained and the strategy could be implemented effectively and safely, the translational potential is fairly obvious.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>B.L.T. is supported by the NUS Graduate School for Integrative Sciences and Engineering. The author is grateful to the reviewers whose very constructive comments greatly improved the manuscript.</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>Conceptualization and writing, B.L.T.</p>
</notes>
<notes>
<title>Funding</title>
<p>This research received no external funding.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The author declares no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-brainsci-09-00238">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sancheti</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cadenas</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Energy metabolism and inflammation in brain aging and Alzheimer’s disease</article-title>
<source/>Free Radic. Biol. Med.
          <year>2016</year>
<volume>100</volume>
<fpage>108</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.04.200</pub-id>
<pub-id pub-id-type="pmid">27154981</pub-id>
</element-citation>
</ref>
<ref id="B2-brainsci-09-00238">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camandola</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mattson</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Brain metabolism in health, aging, and neurodegeneration</article-title>
<source/>EMBO J.
          <year>2017</year>
<volume>36</volume>
<fpage>1474</fpage>
<lpage>1492</lpage>
<pub-id pub-id-type="doi">10.15252/embj.201695810</pub-id>
<pub-id pub-id-type="pmid">28438892</pub-id>
</element-citation>
</ref>
<ref id="B3-brainsci-09-00238">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bose</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ramesh</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Locasale</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Acetate metabolism in physiology, cancer, and beyond</article-title>
<source/>Trends Cell Biol.
          <year>2019</year>
<volume>29</volume>
<fpage>695</fpage>
<lpage>703</lpage>
<pub-id pub-id-type="doi">10.1016/j.tcb.2019.05.005</pub-id>
<pub-id pub-id-type="pmid">31160120</pub-id>
</element-citation>
</ref>
<ref id="B4-brainsci-09-00238">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Icard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fournel</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Alifano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lincet</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Interconnection between metabolism and cell cycle in cancer</article-title>
<source/>Trends Biochem. Sci.
          <year>2019</year>
<volume>44</volume>
<fpage>490</fpage>
<lpage>501</lpage>
<pub-id pub-id-type="doi">10.1016/j.tibs.2018.12.007</pub-id>
<pub-id pub-id-type="pmid">30655165</pub-id>
</element-citation>
</ref>
<ref id="B5-brainsci-09-00238">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papadopoli</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Boulay</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kazak</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pollak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mallette</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Topisirovic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Hulea</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>mTOR as a central regulator of lifespan and aging</article-title>
<source/>F1000Research
          <year>2019</year>
<volume>8</volume>
<pub-id pub-id-type="doi">10.12688/f1000research.17196.1</pub-id>
</element-citation>
</ref>
<ref id="B6-brainsci-09-00238">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasaki</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Metabolic aspects of neuronal degeneration: From a NAD+ point of view</article-title>
<source/>Neurosci. Res.
          <year>2019</year>
<volume>139</volume>
<fpage>9</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1016/j.neures.2018.07.001</pub-id>
<pub-id pub-id-type="pmid">30006197</pub-id>
</element-citation>
</ref>
<ref id="B7-brainsci-09-00238">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quansah</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Peelaerts</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Langston</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Colca</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brundin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration</article-title>
<source/>Mol. Neurodegener.
          <year>2018</year>
<volume>13</volume>
<fpage>28</fpage>
<pub-id pub-id-type="doi">10.1186/s13024-018-0260-x</pub-id>
<pub-id pub-id-type="pmid">29793507</pub-id>
</element-citation>
</ref>
<ref id="B8-brainsci-09-00238">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Tompkins</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>E.B.</given-names>
</name>
</person-group>
<article-title>Regulation of pyruvate metabolism and human disease</article-title>
<source/>Cell. Mol. Life Sci.
          <year>2014</year>
<volume>71</volume>
<fpage>2577</fpage>
<lpage>2604</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-013-1539-2</pub-id>
<pub-id pub-id-type="pmid">24363178</pub-id>
</element-citation>
</ref>
<ref id="B9-brainsci-09-00238">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmieri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Monné</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Discoveries, metabolic roles and diseases of mitochondrial carriers: A review</article-title>
<source/>Biochim. Biophys. Acta
          <year>2016</year>
<volume>1863</volume>
<fpage>2362</fpage>
<lpage>2378</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.03.007</pub-id>
<pub-id pub-id-type="pmid">26968366</pub-id>
</element-citation>
</ref>
<ref id="B10-brainsci-09-00238">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bender</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Martinou</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>The mitochondrial pyruvate carrier in health and disease: To carry or not to carry?</article-title>
<source/>Biochim. Biophys. Acta
          <year>2016</year>
<volume>1863</volume>
<fpage>2436</fpage>
<lpage>2442</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.01.017</pub-id>
<pub-id pub-id-type="pmid">26826034</pub-id>
</element-citation>
</ref>
<ref id="B11-brainsci-09-00238">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dienel</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>The metabolic trinity, glucose-glycogen-lactate, links astrocytes and neurons in brain energetics, signaling, memory, and gene expression</article-title>
<source/>Neurosci. Lett.
          <year>2017</year>
<volume>637</volume>
<fpage>18</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2015.02.052</pub-id>
<pub-id pub-id-type="pmid">25725168</pub-id>
</element-citation>
</ref>
<ref id="B12-brainsci-09-00238">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mergenthaler</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lindauer</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Dienel</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Meisel</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Sugar for the brain: The role of glucose in physiological and pathological brain function</article-title>
<source/>Trends Neurosci.
          <year>2013</year>
<volume>36</volume>
<fpage>587</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2013.07.001</pub-id>
<pub-id pub-id-type="pmid">23968694</pub-id>
</element-citation>
</ref>
<ref id="B13-brainsci-09-00238">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mason</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Lactate shuttles in neuroenergetics-homeostasis, allostasis and beyond</article-title>
<source/>Front. Neurosci.
          <year>2017</year>
<volume>11</volume>
<fpage>43</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2017.00043</pub-id>
<pub-id pub-id-type="pmid">28210209</pub-id>
</element-citation>
</ref>
<ref id="B14-brainsci-09-00238">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>B.Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Sohn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>S.W.</given-names>
</name>
</person-group>
<article-title>Pyruvate administration reduces recurrent/moderate hypoglycemia-induced cortical neuron death in diabetic rats</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e81523</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0081523</pub-id>
<pub-id pub-id-type="pmid">24278448</pub-id>
</element-citation>
</ref>
<ref id="B15-brainsci-09-00238">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Izumi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zorumski</surname>
<given-names>C.F.</given-names>
</name>
</person-group>
<article-title>Neuroprotective effects of pyruvate following NMDA-mediated excitotoxic insults in hippocampal slices</article-title>
<source/>Neurosci. Lett.
          <year>2010</year>
<volume>478</volume>
<fpage>131</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2010.04.078</pub-id>
<pub-id pub-id-type="pmid">20452397</pub-id>
</element-citation>
</ref>
<ref id="B16-brainsci-09-00238">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryou</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Pyruvate protects the brain against ischemia-reperfusion injury by activating the erythropoietin signaling pathway</article-title>
<source/>Stroke
          <year>2012</year>
<volume>43</volume>
<fpage>1101</fpage>
<lpage>1107</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.111.620088</pub-id>
<pub-id pub-id-type="pmid">22282883</pub-id>
</element-citation>
</ref>
<ref id="B17-brainsci-09-00238">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moro</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ghavim</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Hovda</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>R.L.</given-names>
</name>
</person-group>
<article-title>Pyruvate treatment attenuates cerebral metabolic depression and neuronal loss after experimental traumatic brain injury</article-title>
<source/>Brain Res.
          <year>2016</year>
<volume>1642</volume>
<fpage>270</fpage>
<lpage>277</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2016.04.005</pub-id>
<pub-id pub-id-type="pmid">27059390</pub-id>
</element-citation>
</ref>
<ref id="B18-brainsci-09-00238">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popova</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Malkov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ivanov</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Samokhina</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Buldakova</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gubkina</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Osypov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Muhammadiev</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Zilberter</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Molchanov</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Metabolic correction by pyruvate halts acquired epilepsy in multiple rodent models</article-title>
<source/>Neurobiol. Dis.
          <year>2017</year>
<volume>106</volume>
<fpage>244</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2017.07.012</pub-id>
<pub-id pub-id-type="pmid">28709994</pub-id>
</element-citation>
</ref>
<ref id="B19-brainsci-09-00238">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanaka</surname>
<given-names>K.I.</given-names>
</name>
<name>
<surname>Shimoda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Pyruvic acid prevents Cu2+/Zn2+-induced neurotoxicity by suppressing mitochondrial injury</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2018</year>
<volume>495</volume>
<fpage>1335</fpage>
<lpage>1341</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2017.11.152</pub-id>
<pub-id pub-id-type="pmid">29180015</pub-id>
</element-citation>
</ref>
<ref id="B20-brainsci-09-00238">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isopi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Granzotto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Corona</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bomba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ciavardelli</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Curcio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Canzoniero</surname>
<given-names>L.M.T.</given-names>
</name>
<name>
<surname>Navarra</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lattanzio</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Piantelli</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer’s disease without reducing amyloid and tau pathology</article-title>
<source/>Neurobiol. Dis.
          <year>2015</year>
<volume>81</volume>
<fpage>214</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2014.11.013</pub-id>
<pub-id pub-id-type="pmid">25434488</pub-id>
</element-citation>
</ref>
<ref id="B21-brainsci-09-00238">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Systemic pyruvate administration markedly reduces neuronal death and cognitive impairment in a rat model of Alzheimer’s disease</article-title>
<source/>Exp. Neurol.
          <year>2015</year>
<volume>271</volume>
<fpage>145</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2015.06.008</pub-id>
<pub-id pub-id-type="pmid">26057947</pub-id>
</element-citation>
</ref>
<ref id="B22-brainsci-09-00238">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Niyazov</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Rossignol</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Goldenthal</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kahler</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>R.E.</given-names>
</name>
</person-group>
<article-title>Clinical and molecular characteristics of mitochondrial dysfunction in Autism Spectrum Disorder</article-title>
<source/>Mol. Diagn. Ther.
          <year>2018</year>
<volume>22</volume>
<fpage>571</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1007/s40291-018-0352-x</pub-id>
<pub-id pub-id-type="pmid">30039193</pub-id>
</element-citation>
</ref>
<ref id="B23-brainsci-09-00238">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling</article-title>
<source/>Mitochondrion
          <year>2019</year>
<volume>49</volume>
<fpage>35</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1016/j.mito.2019.07.003</pub-id>
<pub-id pub-id-type="pmid">31288090</pub-id>
</element-citation>
</ref>
<ref id="B24-brainsci-09-00238">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cowan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Anichtchik</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Mitochondrial integrity in neurodegeneration</article-title>
<source/>CNS Neurosci. Ther.
          <year>2019</year>
<volume>25</volume>
<fpage>825</fpage>
<lpage>836</lpage>
<pub-id pub-id-type="doi">10.1111/cns.13105</pub-id>
<pub-id pub-id-type="pmid">30746905</pub-id>
</element-citation>
</ref>
<ref id="B25-brainsci-09-00238">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>C.X.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Y.Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial dysfunction in neural injury</article-title>
<source/>Front. Neurosci.
          <year>2019</year>
<volume>13</volume>
<fpage>30</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2019.00030</pub-id>
<pub-id pub-id-type="pmid">30778282</pub-id>
</element-citation>
</ref>
<ref id="B26-brainsci-09-00238">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghosh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tyson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>George</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hildebrandt</surname>
<given-names>E.N.</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Madaj</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Machiela</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Escobar Galvis</surname>
<given-names>M.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson’s disease</article-title>
<source/>Sci. Transl. Med.
          <year>2016</year>
<volume>8</volume>
<fpage>368ra174</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.aag2210</pub-id>
<pub-id pub-id-type="pmid">27928028</pub-id>
</element-citation>
</ref>
<ref id="B27-brainsci-09-00238">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Divakaruni</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Buren</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Martyniuk</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Andreyev</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fields</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Cordes</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>I.J.</given-names>
</name>
<name>
<surname>Bloodgood</surname>
<given-names>B.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of the mitochondrial pyruvate carrier protects from excitotoxic neuronal death</article-title>
<source/>J. Cell Biol.
          <year>2017</year>
<volume>216</volume>
<fpage>1091</fpage>
<lpage>1105</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.201612067</pub-id>
<pub-id pub-id-type="pmid">28254829</pub-id>
</element-citation>
</ref>
<ref id="B28-brainsci-09-00238">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCommis</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Finck</surname>
<given-names>B.N.</given-names>
</name>
</person-group>
<article-title>Mitochondrial pyruvate transport: A historical perspective and future research directions</article-title>
<source/>Biochem. J.
          <year>2015</year>
<volume>466</volume>
<fpage>443</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20141171</pub-id>
<pub-id pub-id-type="pmid">25748677</pub-id>
</element-citation>
</ref>
<ref id="B29-brainsci-09-00238">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>E.B.</given-names>
</name>
</person-group>
<article-title>Functional properties of the mitochondrial carrier system</article-title>
<source/>Trends Cell Biol.
          <year>2017</year>
<volume>27</volume>
<fpage>633</fpage>
<lpage>644</lpage>
<pub-id pub-id-type="doi">10.1016/j.tcb.2017.04.004</pub-id>
<pub-id pub-id-type="pmid">28522206</pub-id>
</element-citation>
</ref>
<ref id="B30-brainsci-09-00238">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hildyard</surname>
<given-names>J.C.W.</given-names>
</name>
<name>
<surname>Ammälä</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dukes</surname>
<given-names>I.D.</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Halestrap</surname>
<given-names>A.P.</given-names>
</name>
</person-group>
<article-title>Identification and characterisation of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrier</article-title>
<source/>Biochim. Biophys. Acta
          <year>2005</year>
<volume>1707</volume>
<fpage>221</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbabio.2004.12.005</pub-id>
<pub-id pub-id-type="pmid">15863100</pub-id>
</element-citation>
</ref>
<ref id="B31-brainsci-09-00238">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Halestrap</surname>
<given-names>A.P.</given-names>
</name>
</person-group>
<article-title>Identification of the protein responsible for pyruvate transport into rat liver and heart mitochondria by specific labelling with [3H] <italic>N</italic>-phenylmaleimide</article-title>
<source/>Biochem. J.
          <year>1981</year>
<volume>196</volume>
<fpage>471</fpage>
<lpage>479</lpage>
<pub-id pub-id-type="doi">10.1042/bj1960471</pub-id>
<pub-id pub-id-type="pmid">7316989</pub-id>
</element-citation>
</ref>
<ref id="B32-brainsci-09-00238">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hildyard</surname>
<given-names>J.C.W.</given-names>
</name>
<name>
<surname>Halestrap</surname>
<given-names>A.P.</given-names>
</name>
</person-group>
<article-title>Identification of the mitochondrial pyruvate carrier in Saccharomyces cerevisiae</article-title>
<source/>Biochem. J.
          <year>2003</year>
<volume>374</volume>
<fpage>607</fpage>
<lpage>611</lpage>
<pub-id pub-id-type="doi">10.1042/bj20030995</pub-id>
<pub-id pub-id-type="pmid">12887330</pub-id>
</element-citation>
</ref>
<ref id="B33-brainsci-09-00238">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Todisco</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Agrimi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Castegna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Identification of the mitochondrial NAD+ transporter in Saccharomyces cerevisiae</article-title>
<source/>J. Biol. Chem.
          <year>2006</year>
<volume>281</volume>
<fpage>1524</fpage>
<lpage>1531</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M510425200</pub-id>
<pub-id pub-id-type="pmid">16291748</pub-id>
</element-citation>
</ref>
<ref id="B34-brainsci-09-00238">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bricker</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Schell</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Orsak</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Boutron</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Cardon</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Van Vranken</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Dephoure</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans</article-title>
<source/>Science
          <year>2012</year>
<volume>337</volume>
<fpage>96</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="doi">10.1126/science.1218099</pub-id>
<pub-id pub-id-type="pmid">22628558</pub-id>
</element-citation>
</ref>
<ref id="B35-brainsci-09-00238">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herzig</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Raemy</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Montessuit</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Veuthey</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Zamboni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Westermann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kunji</surname>
<given-names>E.R.S.</given-names>
</name>
<name>
<surname>Martinou</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Identification and functional expression of the mitochondrial pyruvate carrier</article-title>
<source/>Science
          <year>2012</year>
<volume>337</volume>
<fpage>93</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1126/science.1218530</pub-id>
<pub-id pub-id-type="pmid">22628554</pub-id>
</element-citation>
</ref>
<ref id="B36-brainsci-09-00238">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schell</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The long and winding road to the mitochondrial pyruvate carrier</article-title>
<source/>Cancer Metab.
          <year>2013</year>
<volume>1</volume>
<fpage>6</fpage>
<pub-id pub-id-type="doi">10.1186/2049-3002-1-6</pub-id>
<pub-id pub-id-type="pmid">24280073</pub-id>
</element-citation>
</ref>
<ref id="B37-brainsci-09-00238">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanderperre</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cermakova</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Escoffier</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kaba</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bender</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nef</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Martinou</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>MPC1-like Is a placental mammal-specific mitochondrial pyruvate carrier subunit expressed in postmeiotic male germ cells</article-title>
<source/>J. Biol. Chem.
          <year>2016</year>
<volume>291</volume>
<fpage>16448</fpage>
<lpage>16461</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M116.733840</pub-id>
<pub-id pub-id-type="pmid">27317664</pub-id>
</element-citation>
</ref>
<ref id="B38-brainsci-09-00238">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>NRGA1, a putative mitochondrial pyruvate carrier, mediates ABA regulation of guard cell ion channels and drought stress responses in Arabidopsis</article-title>
<source/>Mol. Plant
          <year>2014</year>
<volume>7</volume>
<fpage>1508</fpage>
<lpage>1521</lpage>
<pub-id pub-id-type="doi">10.1093/mp/ssu061</pub-id>
<pub-id pub-id-type="pmid">24842572</pub-id>
</element-citation>
</ref>
<ref id="B39-brainsci-09-00238">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Mitochondrial pyruvate carrier 1 mediates abscisic acid-regulated stomatal closure and the drought response by affecting cellular pyruvate content in Arabidopsis thaliana</article-title>
<source/>BMC Plant Biol.
          <year>2017</year>
<volume>17</volume>
<elocation-id>217</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12870-017-1175-3</pub-id>
<pub-id pub-id-type="pmid">29166881</pub-id>
</element-citation>
</ref>
<ref id="B40-brainsci-09-00238">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orlandi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Vai</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Rewiring yeast acetate metabolism through MPC1 loss of function leads to mitochondrial damage and decreases chronological lifespan</article-title>
<source/>Microb. Cell
          <year>2014</year>
<volume>1</volume>
<fpage>393</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.15698/mic2014.12.178</pub-id>
<pub-id pub-id-type="pmid">28357219</pub-id>
</element-citation>
</ref>
<ref id="B41-brainsci-09-00238">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vanderperre</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Herzig</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krznar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hörl</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ammar</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Montessuit</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pierredon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zamboni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Martinou</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Embryonic lethality of mitochondrial pyruvate carrier 1 deficient mouse can be rescued by a ketogenic diet</article-title>
<source/>PLoS Genet.
          <year>2016</year>
<volume>12</volume>
<elocation-id>e1006056</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pgen.1006056</pub-id>
<pub-id pub-id-type="pmid">27176894</pub-id>
</element-citation>
</ref>
<ref id="B42-brainsci-09-00238">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vigueira</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>McCommis</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Schweitzer</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Remedi</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Chambers</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Colca</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Kletzien</surname>
<given-names>R.F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial pyruvate carrier 2 hypomorphism in mice leads to defects in glucose-stimulated insulin secretion</article-title>
<source/>Cell Rep.
          <year>2014</year>
<volume>7</volume>
<fpage>2042</fpage>
<lpage>2053</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2014.05.017</pub-id>
<pub-id pub-id-type="pmid">24910426</pub-id>
</element-citation>
</ref>
<ref id="B43-brainsci-09-00238">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oonthonpan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rauckhorst</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Boutron</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>E.B.</given-names>
</name>
</person-group>
<article-title>Two human patient mitochondrial pyruvate carrier mutations reveal distinct molecular mechanisms of dysfunction</article-title>
<source/>JCI Insight
          <year>2019</year>
<volume>5</volume>
<pub-id pub-id-type="doi">10.1172/jci.insight.126132</pub-id>
<pub-id pub-id-type="pmid">31145700</pub-id>
</element-citation>
</ref>
<ref id="B44-brainsci-09-00238">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagampalli</surname>
<given-names>R.S.K.</given-names>
</name>
<name>
<surname>Quesñay</surname>
<given-names>J.E.N.</given-names>
</name>
<name>
<surname>Adamoski</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Islam</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Birch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sebinelli</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Girard</surname>
<given-names>R.M.B.M.</given-names>
</name>
<name>
<surname>Ascenção</surname>
<given-names>C.F.R.</given-names>
</name>
<name>
<surname>Fala</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Pauletti</surname>
<given-names>B.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human mitochondrial pyruvate carrier 2 as an autonomous membrane transporter</article-title>
<source/>Sci. Rep.
          <year>2018</year>
<volume>8</volume>
<fpage>3510</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-018-21740-z</pub-id>
<pub-id pub-id-type="pmid">29472561</pub-id>
</element-citation>
</ref>
<ref id="B45-brainsci-09-00238">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Divakaruni</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Wiley</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Andreyev</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Petrosyan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Loviscach</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wall</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Yadava</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Heuck</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Ferrick</surname>
<given-names>D.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2013</year>
<volume>110</volume>
<fpage>5422</fpage>
<lpage>5427</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1303360110</pub-id>
<pub-id pub-id-type="pmid">23513224</pub-id>
</element-citation>
</ref>
<ref id="B46-brainsci-09-00238">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tavoulari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thangaratnarajah</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mavridou</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Harbour</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Martinou</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Kunji</surname>
<given-names>E.R.</given-names>
</name>
</person-group>
<article-title>The yeast mitochondrial pyruvate carrier is a hetero-dimer in its functional state</article-title>
<source/>EMBO J.
          <year>2019</year>
<volume>38</volume>
<fpage>e100785</fpage>
<pub-id pub-id-type="doi">10.15252/embj.2018100785</pub-id>
<pub-id pub-id-type="pmid">30979775</pub-id>
</element-citation>
</ref>
<ref id="B47-brainsci-09-00238">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Timón-Gómez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Proft</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pascual-Ahuir</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Differential regulation of mitochondrial pyruvate carrier genes modulates respiratory capacity and stress tolerance in yeast</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e79405</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0079405</pub-id>
<pub-id pub-id-type="pmid">24244496</pub-id>
</element-citation>
</ref>
<ref id="B48-brainsci-09-00238">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bender</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pena</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Martinou</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Regulation of mitochondrial pyruvate uptake by alternative pyruvate carrier complexes</article-title>
<source/>EMBO J.
          <year>2015</year>
<volume>34</volume>
<fpage>911</fpage>
<lpage>924</lpage>
<pub-id pub-id-type="doi">10.15252/embj.201490197</pub-id>
<pub-id pub-id-type="pmid">25672363</pub-id>
</element-citation>
</ref>
<ref id="B49-brainsci-09-00238">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patterson</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Cousteils</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Manning Fox</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Joseph</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Mitochondrial metabolism of pyruvate is essential for regulating glucose-stimulated insulin secretion</article-title>
<source/>J. Biol. Chem.
          <year>2014</year>
<volume>289</volume>
<fpage>13335</fpage>
<lpage>13346</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M113.521666</pub-id>
<pub-id pub-id-type="pmid">24675076</pub-id>
</element-citation>
</ref>
<ref id="B50-brainsci-09-00238">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lehmann</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Smith-Oliver</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Wilkison</surname>
<given-names>W.O.</given-names>
</name>
<name>
<surname>Willson</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Kliewer</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)</article-title>
<source/>J. Biol. Chem.
          <year>1995</year>
<volume>270</volume>
<fpage>12953</fpage>
<lpage>12956</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.270.22.12953</pub-id>
<pub-id pub-id-type="pmid">7768881</pub-id>
</element-citation>
</ref>
<ref id="B51-brainsci-09-00238">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hauner</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>The mode of action of thiazolidinediones</article-title>
<source/>Diabetes Metab. Res. Rev.
          <year>2002</year>
<volume>18</volume>
<issue>Suppl. 2</issue>
<fpage>S10</fpage>
<lpage>S15</lpage>
<pub-id pub-id-type="doi">10.1002/dmrr.249</pub-id>
<pub-id pub-id-type="pmid">11921433</pub-id>
</element-citation>
</ref>
<ref id="B52-brainsci-09-00238">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colca</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Cavey</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Holewa</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Brightwell-Conrad</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Wolfe</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Wheeler</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Coulter</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Kilkuskie</surname>
<given-names>P.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e61551</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0061551</pub-id>
<pub-id pub-id-type="pmid">23690925</pub-id>
</element-citation>
</ref>
<ref id="B53-brainsci-09-00238">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Colca</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>VanderLugt</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Shashlo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Orloff</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer</article-title>
<source/>Clin. Pharmacol. Ther.
          <year>2013</year>
<volume>93</volume>
<fpage>352</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1038/clpt.2013.10</pub-id>
<pub-id pub-id-type="pmid">23462886</pub-id>
</element-citation>
</ref>
<ref id="B54-brainsci-09-00238">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Vigueira</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Chambers</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Mitra</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Colca</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Kletzien</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Finck</surname>
<given-names>B.N.</given-names>
</name>
</person-group>
<article-title>Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione</article-title>
<source/>J. Biol. Chem.
          <year>2012</year>
<volume>287</volume>
<fpage>23537</fpage>
<lpage>23548</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.363960</pub-id>
<pub-id pub-id-type="pmid">22621923</pub-id>
</element-citation>
</ref>
<ref id="B55-brainsci-09-00238">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warburg</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Wind</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Negelein</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>The metabolism of tumors in the body</article-title>
<source/>J. Gen. Physiol.
          <year>1927</year>
<volume>8</volume>
<fpage>519</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="doi">10.1085/jgp.8.6.519</pub-id>
<pub-id pub-id-type="pmid">19872213</pub-id>
</element-citation>
</ref>
<ref id="B56-brainsci-09-00238">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vander Heiden</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Cantley</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>C.B.</given-names>
</name>
</person-group>
<article-title>Understanding the Warburg effect: The metabolic requirements of cell proliferation</article-title>
<source/>Science
          <year>2009</year>
<volume>324</volume>
<fpage>1029</fpage>
<lpage>1033</lpage>
<pub-id pub-id-type="doi">10.1126/science.1160809</pub-id>
<pub-id pub-id-type="pmid">19460998</pub-id>
</element-citation>
</ref>
<ref id="B57-brainsci-09-00238">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gopinath</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mazurek</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bamezai</surname>
<given-names>R.N.K.</given-names>
</name>
</person-group>
<article-title>Pyruvate kinase M2 and cancer: An updated assessment</article-title>
<source/>FEBS Lett.
          <year>2014</year>
<volume>588</volume>
<fpage>2685</fpage>
<lpage>2692</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2014.04.011</pub-id>
<pub-id pub-id-type="pmid">24747424</pub-id>
</element-citation>
</ref>
<ref id="B58-brainsci-09-00238">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Augoff</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hryniewicz-Jankowska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tabola</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Lactate dehydrogenase 5: An old friend and a new hope in the war on cancer</article-title>
<source/>Cancer Lett.
          <year>2015</year>
<volume>358</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2014.12.035</pub-id>
<pub-id pub-id-type="pmid">25528630</pub-id>
</element-citation>
</ref>
<ref id="B59-brainsci-09-00238">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Tchernyshyov</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Semenza</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>C.V.</given-names>
</name>
</person-group>
<article-title>HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia</article-title>
<source/>Cell Metab.
          <year>2006</year>
<volume>3</volume>
<fpage>177</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2006.02.002</pub-id>
<pub-id pub-id-type="pmid">16517405</pub-id>
</element-citation>
</ref>
<ref id="B60-brainsci-09-00238">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schell</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Van Vranken</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Egnatchik</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Earl</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>DeBerardinis</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth</article-title>
<source/>Mol. Cell
          <year>2014</year>
<volume>56</volume>
<fpage>400</fpage>
<lpage>413</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2014.09.026</pub-id>
<pub-id pub-id-type="pmid">25458841</pub-id>
</element-citation>
</ref>
<ref id="B61-brainsci-09-00238">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>S.Y.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>MPC1, a key gene in cancer metabolism, is regulated by COUPTFII in human prostate cancer</article-title>
<source/>Oncotarget
          <year>2016</year>
<volume>7</volume>
<fpage>14673</fpage>
<lpage>14683</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.7405</pub-id>
<pub-id pub-id-type="pmid">26895100</pub-id>
</element-citation>
</ref>
<ref id="B62-brainsci-09-00238">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer</article-title>
<source/>BMC Cancer
          <year>2016</year>
<volume>16</volume>
<elocation-id>894</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12885-016-2941-6</pub-id>
<pub-id pub-id-type="pmid">27852261</pub-id>
</element-citation>
</ref>
<ref id="B63-brainsci-09-00238">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Goscinski</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>J.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>1058</fpage>
<lpage>1073</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.13717</pub-id>
<pub-id pub-id-type="pmid">27911865</pub-id>
</element-citation>
</ref>
<ref id="B64-brainsci-09-00238">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schell</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Wisidagama</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Bensard</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tanner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Flores</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mohlman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sorensen</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Earl</surname>
<given-names>C.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Control of intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism</article-title>
<source/>Nat. Cell Biol.
          <year>2017</year>
<volume>19</volume>
<fpage>1027</fpage>
<lpage>1036</lpage>
<pub-id pub-id-type="doi">10.1038/ncb3593</pub-id>
<pub-id pub-id-type="pmid">28812582</pub-id>
</element-citation>
</ref>
<ref id="B65-brainsci-09-00238">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>X.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MPC1 deficiency accelerates lung adenocarcinoma progression through the STAT3 pathway</article-title>
<source/>Cell Death Dis.
          <year>2019</year>
<volume>10</volume>
<fpage>148</fpage>
<pub-id pub-id-type="doi">10.1038/s41419-019-1324-8</pub-id>
<pub-id pub-id-type="pmid">30770798</pub-id>
</element-citation>
</ref>
<ref id="B66-brainsci-09-00238">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takaoka</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Konno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koseki</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Colvin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Asai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tamari</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Satoh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Doki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial pyruvate carrier 1 expression controls cancer epithelial-mesenchymal transition and radioresistance</article-title>
<source/>Cancer Sci.
          <year>2019</year>
<volume>110</volume>
<fpage>1331</fpage>
<lpage>1339</lpage>
<pub-id pub-id-type="doi">10.1111/cas.13980</pub-id>
<pub-id pub-id-type="pmid">30801869</pub-id>
</element-citation>
</ref>
<ref id="B67-brainsci-09-00238">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bader</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Hartig</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Putluri</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Panigrahi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zong</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer</article-title>
<source/>Nat. Metab.
          <year>2019</year>
<volume>1</volume>
<fpage>70</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1038/s42255-018-0002-y</pub-id>
<pub-id pub-id-type="pmid">31198906</pub-id>
</element-citation>
</ref>
<ref id="B68-brainsci-09-00238">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>X.P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Q.G.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial pyruvate carrier 1 functions as a tumor suppressor and predicts the prognosis of human renal cell carcinoma</article-title>
<source/>Lab. Investig.
          <year>2019</year>
<volume>99</volume>
<fpage>191</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="doi">10.1038/s41374-018-0138-0</pub-id>
<pub-id pub-id-type="pmid">30291323</pub-id>
</element-citation>
</ref>
<ref id="B69-brainsci-09-00238">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>J.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro</article-title>
<source/>Oncotarget
          <year>2015</year>
<volume>6</volume>
<fpage>37758</fpage>
<lpage>37769</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.5386</pub-id>
<pub-id pub-id-type="pmid">26413751</pub-id>
</element-citation>
</ref>
<ref id="B70-brainsci-09-00238">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Kan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grigalavicius</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial pyruvate carrier function determines cell stemness and metabolic reprogramming in cancer cells</article-title>
<source/>Oncotarget
          <year>2017</year>
<volume>8</volume>
<fpage>46363</fpage>
<lpage>46380</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.18199</pub-id>
<pub-id pub-id-type="pmid">28624784</pub-id>
</element-citation>
</ref>
<ref id="B71-brainsci-09-00238">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Eguchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kawamoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Konno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Asai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Colvin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takaoka</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Iwagami</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mitochondrial pyruvate carrier modulates the epithelial-mesenchymal transition in cholangiocarcinoma</article-title>
<source/>Oncol. Rep.
          <year>2018</year>
<volume>39</volume>
<fpage>1276</fpage>
<lpage>1282</lpage>
<pub-id pub-id-type="doi">10.3892/or.2017.6172</pub-id>
<pub-id pub-id-type="pmid">29286150</pub-id>
</element-citation>
</ref>
<ref id="B72-brainsci-09-00238">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corbet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bastien</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Draoui</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Doix</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mignion</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>B.F.</given-names>
</name>
<name>
<surname>Marchand</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vanherck</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Chaltin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schakman</surname>
<given-names>O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects</article-title>
<source/>Nat. Commun.
          <year>2018</year>
<volume>9</volume>
<fpage>1208</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-018-03525-0</pub-id>
<pub-id pub-id-type="pmid">29572438</pub-id>
</element-citation>
</ref>
<ref id="B73-brainsci-09-00238">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owen</surname>
<given-names>O.E.</given-names>
</name>
<name>
<surname>Kalhan</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Hanson</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>The key role of anaplerosis and cataplerosis for citric acid cycle function</article-title>
<source/>J. Biol. Chem.
          <year>2002</year>
<volume>277</volume>
<fpage>30409</fpage>
<lpage>30412</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.R200006200</pub-id>
<pub-id pub-id-type="pmid">12087111</pub-id>
</element-citation>
</ref>
<ref id="B74-brainsci-09-00238">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sudderth</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bachoo</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Bachoo</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>DeBerardinis</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling</article-title>
<source/>Cancer Res.
          <year>2009</year>
<volume>69</volume>
<fpage>7986</fpage>
<lpage>7993</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2266</pub-id>
<pub-id pub-id-type="pmid">19826036</pub-id>
</element-citation>
</ref>
<ref id="B75-brainsci-09-00238">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hensley</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wasti</surname>
<given-names>A.T.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sudderth</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Calvaruso</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Lumata</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mitsche</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport</article-title>
<source/>Mol. Cell
          <year>2014</year>
<volume>56</volume>
<fpage>414</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2014.09.025</pub-id>
<pub-id pub-id-type="pmid">25458842</pub-id>
</element-citation>
</ref>
<ref id="B76-brainsci-09-00238">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vacanti</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Divakaruni</surname>
<given-names>A.S.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Ciaraldi</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Metallo</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Regulation of substrate utilization by the mitochondrial pyruvate carrier</article-title>
<source/>Mol. Cell
          <year>2014</year>
<volume>56</volume>
<fpage>425</fpage>
<lpage>435</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2014.09.024</pub-id>
<pub-id pub-id-type="pmid">25458843</pub-id>
</element-citation>
</ref>
<ref id="B77-brainsci-09-00238">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Sultana</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Rauckhorst</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Oonthonpan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tompkins</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pewa</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>K.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hepatic mitochondrial pyruvate carrier 1 is required for efficient regulation of gluconeogenesis and whole-body glucose homeostasis</article-title>
<source/>Cell Metab.
          <year>2015</year>
<volume>22</volume>
<fpage>669</fpage>
<lpage>681</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2015.07.027</pub-id>
<pub-id pub-id-type="pmid">26344103</pub-id>
</element-citation>
</ref>
<ref id="B78-brainsci-09-00238">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCommis</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>W.G.</given-names>
</name>
<name>
<surname>Colca</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Kletzien</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Finck</surname>
<given-names>B.N.</given-names>
</name>
</person-group>
<article-title>Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling</article-title>
<source/>Cell Metab.
          <year>2015</year>
<volume>22</volume>
<fpage>682</fpage>
<lpage>694</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2015.07.028</pub-id>
<pub-id pub-id-type="pmid">26344101</pub-id>
</element-citation>
</ref>
<ref id="B79-brainsci-09-00238">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Oonthonpan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sheldon</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Rauckhorst</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tompkins</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Grzesik</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Scerbo</surname>
<given-names>D.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impaired skeletal muscle mitochondrial pyruvate uptake rewires glucose metabolism to drive whole-body leanness</article-title>
<source/>eLife
          <year>2019</year>
<volume>8</volume>
<fpage>e45873</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.45873</pub-id>
<pub-id pub-id-type="pmid">31305240</pub-id>
</element-citation>
</ref>
<ref id="B80-brainsci-09-00238">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nordströma</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Beauvais</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pulikkaparambil Sasidharan</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Lundblad</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fuchs</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Lipton</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Roholt</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Medicetty</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson’s disease</article-title>
<source/>Neurobiol. Dis.
          <year>2015</year>
<volume>73</volume>
<fpage>70</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2014.09.012</pub-id>
<pub-id pub-id-type="pmid">25281317</pub-id>
</element-citation>
</ref>
<ref id="B81-brainsci-09-00238">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perluigi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Di Domenico</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Butterfield</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy</article-title>
<source/>Neurobiol. Dis.
          <year>2015</year>
<volume>84</volume>
<fpage>39</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2015.03.014</pub-id>
<pub-id pub-id-type="pmid">25796566</pub-id>
</element-citation>
</ref>
<ref id="B82-brainsci-09-00238">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jahrling</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Laberge</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Age-related neurodegeneration prevention through mTOR inhibition: Potential mechanisms and remaining questions</article-title>
<source/>Curr. Top. Med. Chem.
          <year>2015</year>
<volume>15</volume>
<fpage>2139</fpage>
<lpage>2151</lpage>
<pub-id pub-id-type="doi">10.2174/1568026615666150610125856</pub-id>
<pub-id pub-id-type="pmid">26059360</pub-id>
</element-citation>
</ref>
<ref id="B83-brainsci-09-00238">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frake</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Ricketts</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Menzies</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Rubinsztein</surname>
<given-names>D.C.</given-names>
</name>
</person-group>
<article-title>Autophagy and neurodegeneration</article-title>
<source/>J. Clin. Investig.
          <year>2015</year>
<volume>125</volume>
<fpage>65</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1172/JCI73944</pub-id>
<pub-id pub-id-type="pmid">25654552</pub-id>
</element-citation>
</ref>
<ref id="B84-brainsci-09-00238">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dello Russo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lisi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tringali</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Navarra</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation</article-title>
<source/>Biochem. Pharmacol.
          <year>2009</year>
<volume>78</volume>
<fpage>1242</fpage>
<lpage>1251</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2009.06.097</pub-id>
<pub-id pub-id-type="pmid">19576187</pub-id>
</element-citation>
</ref>
<ref id="B85-brainsci-09-00238">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>F.D.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type</article-title>
<source/>FASEB J.
          <year>2016</year>
<volume>30</volume>
<fpage>3388</fpage>
<lpage>3399</lpage>
<pub-id pub-id-type="doi">10.1096/fj.201600495R</pub-id>
<pub-id pub-id-type="pmid">27342766</pub-id>
</element-citation>
</ref>
<ref id="B86-brainsci-09-00238">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srivastava</surname>
<given-names>I.N.</given-names>
</name>
<name>
<surname>Shperdheja</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Baybis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Crino</surname>
<given-names>P.B.</given-names>
</name>
</person-group>
<article-title>mTOR pathway inhibition prevents neuroinflammation and neuronal death in a mouse model of cerebral palsy</article-title>
<source/>Neurobiol. Dis.
          <year>2016</year>
<volume>85</volume>
<fpage>144</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2015.10.001</pub-id>
<pub-id pub-id-type="pmid">26459113</pub-id>
</element-citation>
</ref>
<ref id="B87-brainsci-09-00238">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKenna</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Stridh</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>McNair</surname>
<given-names>L.F.</given-names>
</name>
<name>
<surname>Sonnewald</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Waagepetersen</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Schousboe</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Glutamate oxidation in astrocytes: Roles of glutamate dehydrogenase and aminotransferases</article-title>
<source/>J. Neurosci. Res.
          <year>2016</year>
<volume>94</volume>
<fpage>1561</fpage>
<lpage>1571</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.23908</pub-id>
<pub-id pub-id-type="pmid">27629247</pub-id>
</element-citation>
</ref>
<ref id="B88-brainsci-09-00238">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hertz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rothman</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>Glutamine-glutamate cycle flux is similar in cultured astrocytes and brain and both glutamate production and oxidation are mainly catalyzed by Aspartate Aminotransferase</article-title>
<source/>Biology
          <year>2017</year>
<volume>6</volume>
<elocation-id>17</elocation-id>
<pub-id pub-id-type="doi">10.3390/biology6010017</pub-id>
</element-citation>
</ref>
<ref id="B89-brainsci-09-00238">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cleghorn</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Contreras</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lindsay</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rountree</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Chertov</surname>
<given-names>A.O.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Sahaboglu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Linton</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sadilek</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina</article-title>
<source/>J. Biol. Chem.
          <year>2013</year>
<volume>288</volume>
<fpage>36129</fpage>
<lpage>36140</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M113.507285</pub-id>
<pub-id pub-id-type="pmid">24187136</pub-id>
</element-citation>
</ref>
<ref id="B90-brainsci-09-00238">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saxton</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>mTOR signaling in growth, metabolism, and disease</article-title>
<source/>Cell
          <year>2017</year>
<volume>168</volume>
<fpage>960</fpage>
<lpage>976</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2017.02.004</pub-id>
<pub-id pub-id-type="pmid">28283069</pub-id>
</element-citation>
</ref>
<ref id="B91-brainsci-09-00238">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardie</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>AMPK: Positive and negative regulation, and its role in whole-body energy homeostasis</article-title>
<source/>Curr. Opin. Cell Biol.
          <year>2014</year>
<volume>33</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.ceb.2014.09.004</pub-id>
<pub-id pub-id-type="pmid">25259783</pub-id>
</element-citation>
</ref>
<ref id="B92-brainsci-09-00238">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gwinn</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Shackelford</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Egan</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Mihaylova</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Mery</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vasquez</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Turk</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>AMPK phosphorylation of raptor mediates a metabolic checkpoint</article-title>
<source/>Mol. Cell
          <year>2008</year>
<volume>30</volume>
<fpage>214</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2008.03.003</pub-id>
<pub-id pub-id-type="pmid">18439900</pub-id>
</element-citation>
</ref>
<ref id="B93-brainsci-09-00238">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inoki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>TSC2 mediates cellular energy response to control cell growth and survival</article-title>
<source/>Cell
          <year>2003</year>
<volume>115</volume>
<fpage>577</fpage>
<lpage>590</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(03)00929-2</pub-id>
<pub-id pub-id-type="pmid">14651849</pub-id>
</element-citation>
</ref>
<ref id="B94-brainsci-09-00238">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>TSC1/TSC2 signaling in the CNS</article-title>
<source/>FEBS Lett.
          <year>2011</year>
<volume>585</volume>
<fpage>973</fpage>
<lpage>980</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2011.02.001</pub-id>
<pub-id pub-id-type="pmid">21329690</pub-id>
</element-citation>
</ref>
<ref id="B95-brainsci-09-00238">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Fenyk-Melody</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ventre</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Doebber</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fujii</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of AMP-activated protein kinase in mechanism of metformin action</article-title>
<source/>J. Clin. Investig.
          <year>2001</year>
<volume>108</volume>
<fpage>1167</fpage>
<lpage>1174</lpage>
<pub-id pub-id-type="doi">10.1172/JCI13505</pub-id>
<pub-id pub-id-type="pmid">11602624</pub-id>
</element-citation>
</ref>
<ref id="B96-brainsci-09-00238">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marinangeli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Didier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vingtdeux</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>AMPK in neurodegenerative diseases: Implications and therapeutic perspectives</article-title>
<source/>Curr. Drug Targets
          <year>2016</year>
<volume>17</volume>
<fpage>890</fpage>
<lpage>907</lpage>
<pub-id pub-id-type="doi">10.2174/1389450117666160201105645</pub-id>
<pub-id pub-id-type="pmid">26073858</pub-id>
</element-citation>
</ref>
<ref id="B97-brainsci-09-00238">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rotermund</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Machetanz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>The therapeutic potential of Metformin in neurodegenerative diseases</article-title>
<source/>Front. Endocrinol.
          <year>2018</year>
<volume>9</volume>
<fpage>400</fpage>
<pub-id pub-id-type="doi">10.3389/fendo.2018.00400</pub-id>
</element-citation>
</ref>
<ref id="B98-brainsci-09-00238">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gantois</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Popic</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Khoutorsky</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sonenberg</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Metformin for treatment of Fragile X Syndrome and other neurological disorders</article-title>
<source/>Annu. Rev. Med.
          <year>2019</year>
<volume>70</volume>
<fpage>167</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-med-081117-041238</pub-id>
<pub-id pub-id-type="pmid">30365357</pub-id>
</element-citation>
</ref>
<ref id="B99-brainsci-09-00238">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Felig</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>The glucose-alanine cycle</article-title>
<source/>Metabolism
          <year>1973</year>
<volume>22</volume>
<fpage>179</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1016/0026-0495(73)90269-2</pub-id>
<pub-id pub-id-type="pmid">4567003</pub-id>
</element-citation>
</ref>
<ref id="B100-brainsci-09-00238">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corbet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Feron</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Metabolic and mind shifts: From glucose to glutamine and acetate addictions in cancer</article-title>
<source/>Curr. Opin. Clin. Nutr. Metab. Care
          <year>2015</year>
<volume>18</volume>
<fpage>346</fpage>
<lpage>353</lpage>
<pub-id pub-id-type="doi">10.1097/MCO.0000000000000178</pub-id>
<pub-id pub-id-type="pmid">26001655</pub-id>
</element-citation>
</ref>
<ref id="B101-brainsci-09-00238">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goubert</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mircheva</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lasorsa</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Melon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Profilo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sutera</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Becq</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Palmieri</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Aniksztejn</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of the mitochondrial glutamate carrier SLC25A22 in astrocytes leads to intracellular glutamate accumulation</article-title>
<source/>Front. Cell. Neurosci.
          <year>2017</year>
<volume>11</volume>
<fpage>149</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2017.00149</pub-id>
<pub-id pub-id-type="pmid">28620281</pub-id>
</element-citation>
</ref>
<ref id="B102-brainsci-09-00238">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandrekar-Colucci</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karlo</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Landreth</surname>
<given-names>G.E.</given-names>
</name>
</person-group>
<article-title>Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease</article-title>
<source/>J. Neurosci.
          <year>2012</year>
<volume>32</volume>
<fpage>10117</fpage>
<lpage>10128</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5268-11.2012</pub-id>
<pub-id pub-id-type="pmid">22836247</pub-id>
</element-citation>
</ref>
<ref id="B103-brainsci-09-00238">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pérez</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Quintanilla</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Therapeutic actions of the Thiazolidinediones in Alzheimer’s disease</article-title>
<source/>PPAR Res.
          <year>2015</year>
<volume>2015</volume>
<fpage>957248</fpage>
<pub-id pub-id-type="doi">10.1155/2015/957248</pub-id>
<pub-id pub-id-type="pmid">26587016</pub-id>
</element-citation>
</ref>
<ref id="B104-brainsci-09-00238">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0123864</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0123864</pub-id>
<pub-id pub-id-type="pmid">25875370</pub-id>
</element-citation>
</ref>
<ref id="B105-brainsci-09-00238">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galimberti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Scarpini</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Pioglitazone for the treatment of Alzheimer’s disease</article-title>
<source/>Expert Opin. Investig. Drugs
          <year>2017</year>
<volume>26</volume>
<fpage>97</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1080/13543784.2017.1265504</pub-id>
<pub-id pub-id-type="pmid">27885860</pub-id>
</element-citation>
</ref>
<ref id="B106-brainsci-09-00238">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brauer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bhaskaran</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chaturvedi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dexter</surname>
<given-names>D.T.</given-names>
</name>
<name>
<surname>Smeeth</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Douglas</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Glitazone treatment and incidence of Parkinson’s disease among people with diabetes: A retrospective cohort study</article-title>
<source/>PLoS Med.
          <year>2015</year>
<volume>12</volume>
<elocation-id>e1001854</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1001854</pub-id>
<pub-id pub-id-type="pmid">26196151</pub-id>
</element-citation>
</ref>
<ref id="B107-brainsci-09-00238">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<collab>NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators</collab>
</person-group>
<article-title>Pioglitazone in early Parkinson’s disease: A phase 2, multicentre, double-blind, randomised trial</article-title>
<source/>Lancet Neurol.
          <year>2015</year>
<volume>14</volume>
<fpage>795</fpage>
<lpage>803</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00144-1</pub-id>
<pub-id pub-id-type="pmid">26116315</pub-id>
</element-citation>
</ref>
<ref id="B108-brainsci-09-00238">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Connolly</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Bykov</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gagne</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Thiazolidinediones and Parkinson disease: A cohort study</article-title>
<source/>Am. J. Epidemiol.
          <year>2015</year>
<volume>182</volume>
<fpage>936</fpage>
<lpage>944</lpage>
<pub-id pub-id-type="doi">10.1093/aje/kwv109</pub-id>
<pub-id pub-id-type="pmid">26493264</pub-id>
</element-citation>
</ref>
<ref id="B109-brainsci-09-00238">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nissanka</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Peralta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brambilla</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Moraes</surname>
<given-names>C.T.</given-names>
</name>
</person-group>
<article-title>Pioglitazone ameliorates the phenotype of a novel Parkinson’s disease mouse model by reducing neuroinflammation</article-title>
<source/>Mol. Neurodegener.
          <year>2016</year>
<volume>11</volume>
<fpage>25</fpage>
<pub-id pub-id-type="doi">10.1186/s13024-016-0090-7</pub-id>
<pub-id pub-id-type="pmid">27038906</pub-id>
</element-citation>
</ref>
<ref id="B110-brainsci-09-00238">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brakedal</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Flønes</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Reiter</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Torkildsen</surname>
<given-names>Ø.</given-names>
</name>
<name>
<surname>Dölle</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Assmus</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Haugarvoll</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tzoulis</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Glitazone use associated with reduced risk of Parkinson’s disease</article-title>
<source/>Mov. Disord.
          <year>2017</year>
<volume>32</volume>
<fpage>1594</fpage>
<lpage>1599</lpage>
<pub-id pub-id-type="doi">10.1002/mds.27128</pub-id>
<pub-id pub-id-type="pmid">28861893</pub-id>
</element-citation>
</ref>
<ref id="B111-brainsci-09-00238">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schütz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Reimann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dumitrescu-Ozimek</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kappes-Horn</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Landreth</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Schürmann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Heneka</surname>
<given-names>M.T.</given-names>
</name>
</person-group>
<article-title>The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice</article-title>
<source/>J. Neurosci.
          <year>2005</year>
<volume>25</volume>
<fpage>7805</fpage>
<lpage>7812</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2038-05.2005</pub-id>
<pub-id pub-id-type="pmid">16120782</pub-id>
</element-citation>
</ref>
<ref id="B112-brainsci-09-00238">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joardar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Menzl</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Podolsky</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Manzo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Estes</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Ashford</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zarnescu</surname>
<given-names>D.C.</given-names>
</name>
</person-group>
<article-title>PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43</article-title>
<source/>Hum. Mol. Genet.
          <year>2015</year>
<volume>24</volume>
<fpage>1741</fpage>
<lpage>1754</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddu587</pub-id>
<pub-id pub-id-type="pmid">25432537</pub-id>
</element-citation>
</ref>
<ref id="B113-brainsci-09-00238">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiang</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Chern</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>R.N.</given-names>
</name>
</person-group>
<article-title>PPARgamma rescue of the mitochondrial dysfunction in Huntington’s disease</article-title>
<source/>Neurobiol. Dis.
          <year>2012</year>
<volume>45</volume>
<fpage>322</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2011.08.016</pub-id>
<pub-id pub-id-type="pmid">21907283</pub-id>
</element-citation>
</ref>
<ref id="B114-brainsci-09-00238">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Albertz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Rudow</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Troncoso</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington’s disease</article-title>
<source/>J. Neurochem.
          <year>2013</year>
<volume>125</volume>
<fpage>410</fpage>
<lpage>419</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.12190</pub-id>
<pub-id pub-id-type="pmid">23373812</pub-id>
</element-citation>
</ref>
<ref id="B115-brainsci-09-00238">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiang</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Nicol</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Yen</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>R.N.</given-names>
</name>
</person-group>
<article-title>Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells</article-title>
<source/>Exp. Cell Res.
          <year>2015</year>
<volume>338</volume>
<fpage>183</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="doi">10.1016/j.yexcr.2015.09.005</pub-id>
<pub-id pub-id-type="pmid">26362846</pub-id>
</element-citation>
</ref>
<ref id="B116-brainsci-09-00238">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leszek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Trypka</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tarasov</surname>
<given-names>V.V.</given-names>
</name>
<name>
<surname>Ashraf</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Aliev</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Type 3 Diabetes Mellitus: A novel implication of Alzheimers disease</article-title>
<source/>Curr. Top. Med. Chem.
          <year>2017</year>
<volume>17</volume>
<fpage>1331</fpage>
<lpage>1335</lpage>
<pub-id pub-id-type="doi">10.2174/1568026617666170103163403</pub-id>
<pub-id pub-id-type="pmid">28049395</pub-id>
</element-citation>
</ref>
<ref id="B117-brainsci-09-00238">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pearson-Leary</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McNay</surname>
<given-names>E.C.</given-names>
</name>
</person-group>
<article-title>Novel roles for the insulin-regulated Glucose Transporter-4 in hippocampally dependent memory</article-title>
<source/>J. Neurosci.
          <year>2016</year>
<volume>36</volume>
<fpage>11851</fpage>
<lpage>11864</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1700-16.2016</pub-id>
<pub-id pub-id-type="pmid">27881773</pub-id>
</element-citation>
</ref>
<ref id="B118-brainsci-09-00238">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spinelli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fusco</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grassi</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Brain insulin resistance and hippocampal plasticity: Mechanisms and biomarkers of cognitive decline</article-title>
<source/>Front. Neurosci.
          <year>2019</year>
<volume>13</volume>
<fpage>788</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2019.00788</pub-id>
<pub-id pub-id-type="pmid">31417349</pub-id>
</element-citation>
</ref>
<ref id="B119-brainsci-09-00238">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Craig</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Parvez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Issberner</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer’s Disease in transgenic mice</article-title>
<source/>Behav. Brain Res.
          <year>2019</year>
<volume>372</volume>
<fpage>112015</fpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2019.112015</pub-id>
<pub-id pub-id-type="pmid">31255671</pub-id>
</element-citation>
</ref>
<ref id="B120-brainsci-09-00238">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgan</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Inzucchi</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Puelles</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jenkins-Jones</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Currie</surname>
<given-names>C.J.</given-names>
</name>
</person-group>
<article-title>Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis</article-title>
<source/>Diabetes Obes. Metab.
          <year>2018</year>
<volume>20</volume>
<fpage>2140</fpage>
<lpage>2147</lpage>
<pub-id pub-id-type="doi">10.1111/dom.13344</pub-id>
<pub-id pub-id-type="pmid">29732718</pub-id>
</element-citation>
</ref>
<ref id="B121-brainsci-09-00238">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Saver</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Ovbiagele</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Pioglitazone for secondary stroke prevention: A systematic review and meta-analysis</article-title>
<source/>Stroke
          <year>2017</year>
<volume>48</volume>
<fpage>388</fpage>
<lpage>393</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.116.013977</pub-id>
<pub-id pub-id-type="pmid">27999139</pub-id>
</element-citation>
</ref>
<ref id="B122-brainsci-09-00238">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yaghi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Furie</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Viscoli</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Kamel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gorman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dearborn</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Inzucchi</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Lovejoy</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Kasner</surname>
<given-names>S.E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: A planned secondary analysis of the IRIS trial (Insulin Resistance Intervention After Stroke)</article-title>
<source/>Circulation
          <year>2018</year>
<volume>137</volume>
<fpage>455</fpage>
<lpage>463</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.030458</pub-id>
<pub-id pub-id-type="pmid">29084736</pub-id>
</element-citation>
</ref>
<ref id="B123-brainsci-09-00238">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGuire</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Correll</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Lowery</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Rhame</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Anwar</surname>
<given-names>F.N.</given-names>
</name>
<name>
<surname>McCullumsmith</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>Ngwenya</surname>
<given-names>L.B.</given-names>
</name>
</person-group>
<article-title>Pioglitazone improves working memory performance when administered in chronic TBI</article-title>
<source/>Neurobiol. Dis.
          <year>2019</year>
<volume>132</volume>
<fpage>104611</fpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2019.104611</pub-id>
<pub-id pub-id-type="pmid">31513844</pub-id>
</element-citation>
</ref>
<ref id="B124-brainsci-09-00238">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phelix</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bourdon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dugan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Villareal</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>MSDC-0160 and MSDC-0602 binding with human mitochondrial pyruvate carrier (MPC) 1 and 2 heterodimer: PPARγ activating and sparing TZDs as therapeutics</article-title>
<source/>Int. J. Knowl. Knowl. Bioinform.
          <year>2017</year>
<volume>7</volume>
<fpage>43</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.4018/IJKDB.2017070103</pub-id>
</element-citation>
</ref>
<ref id="B125-brainsci-09-00238">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nancolas</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nath</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Leeper</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>I.A.</given-names>
</name>
<name>
<surname>Glickson</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Halestrap</surname>
<given-names>A.P.</given-names>
</name>
</person-group>
<article-title>The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters</article-title>
<source/>Biochem. J.
          <year>2016</year>
<volume>473</volume>
<fpage>929</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20151120</pub-id>
<pub-id pub-id-type="pmid">26831515</pub-id>
</element-citation>
</ref>
<ref id="B126-brainsci-09-00238">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mansi</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>de Graeff</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Newell</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Glaholm</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Button</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Leach</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>Payne</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>I.E.</given-names>
</name>
</person-group>
<article-title>A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer</article-title>
<source/>Br. J. Cancer
          <year>1991</year>
<volume>64</volume>
<fpage>593</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="doi">10.1038/bjc.1991.356</pub-id>
<pub-id pub-id-type="pmid">1911204</pub-id>
</element-citation>
</ref>
<ref id="B127-brainsci-09-00238">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ouari</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zielonka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Zielonka</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Weh</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis</article-title>
<source/>Nat. Commun.
          <year>2019</year>
<volume>10</volume>
<fpage>2205</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-019-10042-1</pub-id>
<pub-id pub-id-type="pmid">31101821</pub-id>
</element-citation>
</ref>
<ref id="B128-brainsci-09-00238">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Cosimo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ferretti</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Papaldo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Carlini</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fabi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cognetti</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors</article-title>
<source/>Drugs Today
          <year>2003</year>
<volume>39</volume>
<fpage>157</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1358/dot.2003.39.3.799451</pub-id>
<pub-id pub-id-type="pmid">12730701</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="brainsci-09-00238-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>A schematic diagram summarizing the pathways and possible mechanisms underlying mitochondrial pyruvate carrier (MPC) inhibition-mediated neuroprotection that has recently came to light. Metabolic adaptations in a neuronal cell that underlie neuroprotection could result in an Inhibition of mechanistic target of rapamycin complex 1 (mTORC1) via AMP-dependent protein kinase (AMPK) activation due to increased AMP/ATP ratio (<bold>A</bold>), which promotes neuroprotective autophagy. AMPK could inhibit mTORC1 by phosphorylating Raptor (R) or Tuberous sclerosis complex 2 (TSC2). Metabolic adaptations could also promote a switch to oxidizing alternative substrates like glutamate (<bold>B</bold>), which may reduce the synaptic glutamate pool, thus attenuating excitoxicity. Glutamate feeding into tricarboxylic acid (TCA) cycle (conversion of glutamate to <italic>α</italic>-ketoglutarate by glutamate dehydrogenase sustains the anaplerotic needs of the cell. Reduced mitochondrial pyruvate import and feeding into the TCA cycle may conceivably also be compensated by enhanced alanine-pyruvate cycling.</p>
</caption>
<graphic xlink:href="brainsci-09-00238-g001"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>